Setara Biosciences Launches With $90 Million and a TRPV4 Program Already in Human Testing
Setara Biosciences has emerged with $90 million in Series A financing and a lead drug already in the clinic, a combination that gives the new company unusual early momentum. The San Diego startup is built around STAR-0871, formerly ABS-0871, a small molecule TRPV4 inhibitor being developed first for Charcot-Marie-Tooth disease type 2C and then for overactive bladder. The same target sits at the center of both programs, but the clinical logic differs sharply: one disease is rare and driven by inherited nerve injury, while the other is common and tied to abnormal bladder signaling.
This is the kind of program that tries to make a rare disease asset pay off twice. If the biology holds, a single ion channel could support development in a small, genetically defined disorder and in a far larger condition where current treatment options still leave many patients undertreated.
A Rare Neuromuscular Disease Anchors the First Development Path
Charcot-Marie-Tooth disease type 2C is a rare neuromuscular disorder with no FDA-approved therapy. In this subtype, mutations in the TRPV4 gene produce channels that are abnormally active, and that overactivity contributes to the peripheral nerve damage that defines the disease. Setara’s drug is designed to selectively inhibit that channel, aiming to blunt the pathologic signal at its source rather than simply manage symptoms downstream.
The appeal of this strategy is straightforward. Ion channels are not abstract molecular curiosities in this setting; they are part of the disease machinery itself. When a channel becomes too active, nerve cells and the tissues they support can be pushed into a state of chronic dysfunction. A targeted inhibitor gives investigators a mechanistic shot at interrupting that process, which is exactly why TRPV4 has drawn attention as a precision medicine target.
The program also reflects the broader strategy that produced it. Actio Biosciences used a human genetics platform to identify targets and connect them to disease biology, then built a pipeline around those discoveries. Setara now inherits the rare-disease portion of that work, with a lead asset that has already moved beyond discovery and into early clinical evaluation.
Human Data Are Beginning to Arrive
A Phase 1 study of the TRPV4 inhibitor was already underway when Jazz Pharmaceuticals announced its acquisition of Actio Biosciences in August. Setara says the healthy volunteer portion of that trial is now complete. Next year, the study is expected to expand into a Phase 1b portion enrolling patients with Charcot-Marie-Tooth disease.
This step matters because healthy-volunteer safety alone cannot answer the central question in a disease like CMT2C: whether the drug reaches the right tissue, engages the target, and does so without worsening neurologic function. Early patient enrollment will start to test the translational bridge between molecular inhibition and real-world neuromuscular benefit. In rare genetic disease, the distance between those two points can be wide, and it often takes careful dose exploration before a signal becomes visible.
The planned progression from healthy subjects to affected patients is also a reminder of how early this program still is. The evidence base remains small, and the next stage will need to clarify not only safety and tolerability, but also whether the pharmacology matches the inherited defect that justifies the program in the first place.
Overactive Bladder Gives the Same Target a Much Larger Stage
TRPV4 is not confined to peripheral nerves. It also has a role in sensing bladder fullness, which is why Setara plans to pursue overactive bladder in parallel with the rare-disease program. That indication offers a very different commercial and clinical path. Overactive bladder affects millions of people, yet available therapies still have limited efficacy for many patients, leaving room for better symptom control and, ideally, fewer trade-offs.
The biological rationale is attractive. If TRPV4 helps detect bladder distension, then selective inhibition may alter the sensory signaling that contributes to urgency and frequency. In practical terms, that could mean a therapy aimed at the upstream trigger rather than the bladder’s final spasmodic response. The company plans a separate Phase 2a study in overactive bladder, creating a second clinical track that could reveal whether the same mechanism can travel from a rare inherited neuropathy into a far broader urologic disorder.
This split development plan carries both opportunity and risk. A target that is relevant in two anatomically distinct systems can broaden the drug’s value if the data are clean. The same breadth can also complicate dosing, because the therapeutic window in nerves may not mirror the window in the lower urinary tract. Those are the kinds of questions that only clinical testing can settle.
Setara Inherits More Than One Asset From Actio
STAR-0871 is the lead, but not the only program to come from Actio’s research platform. Setara also holds discovery-stage assets for epilepsy and migraine, with targets that remain undisclosed. The startup therefore begins life with a pipeline strategy rather than a single-asset bet, though only the TRPV4 program is currently described in clinical development terms.
The Jazz-Actio transaction provides the backdrop for all of this. Jazz acquired Actio for its epilepsy drug candidate, and the rare-disease assets were spun into the new company. The transaction closed in September and included $820 million upfront, with another $500 million tied to milestones. Setara’s formation turns that corporate restructuring into an operating biotech, now funded to push the inherited programs forward.
David Goldstein, Actio’s former chief executive, now serves as president and executive chair of Setara. In a prepared statement, he framed the company as a way to continue a pipeline of rare-disease programs with the potential to reach broader patient populations. The financing syndicate reflects that continuity. Deerfield Management, Canaan, Droia Ventures, EcoR1, Euclidean Capital, and Regeneron Ventures all backed Actio previously and returned for the Series A, while Jazz joined as a new investor.
The Next Readouts Will Test Whether Channel Biology Can Travel
The core question for Setara is whether a single ion channel can support two credible therapeutic stories at once. In CMT2C, the case rests on genetics: an overactive channel appears to drive nerve injury, and inhibition could theoretically slow or alter the course of the disorder. In overactive bladder, the same target is linked to bladder fullness signaling, creating a separate route to efficacy in a far more common disease.
What happens next will depend on whether the early human data line up with that biology. Healthy-volunteer completion is an important start, but the real test comes in patients, where dosing, tolerability, and any hint of disease modification will determine whether this precision medicine story can move beyond rationale and into treatment reality. Setara now has the capital to try, but the clinical bar remains high, especially for a drug intended to work by changing ion channel behavior in two very different tissues.